Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities
Treatment of pediatric-onset multiple sclerosis (POMS) has been tailored after observational studies and data obtained from clinical trials in adult-onset multiple sclerosis (AOMS) patients. There are an increasing number of new therapeutic agents for AOMS, and many will be formally studied for use...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-05-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.676095/full |
| _version_ | 1818639971484958720 |
|---|---|
| author | Monica Margoni Monica Margoni Francesca Rinaldi Paola Perini Paolo Gallo Paolo Gallo |
| author_facet | Monica Margoni Monica Margoni Francesca Rinaldi Paola Perini Paolo Gallo Paolo Gallo |
| author_sort | Monica Margoni |
| collection | DOAJ |
| description | Treatment of pediatric-onset multiple sclerosis (POMS) has been tailored after observational studies and data obtained from clinical trials in adult-onset multiple sclerosis (AOMS) patients. There are an increasing number of new therapeutic agents for AOMS, and many will be formally studied for use also in POMS. However, there are important efficacy and safety concerns regarding the use of these therapies in children and young adults. This review will discuss the current state of the art of POMS therapy and will focus on the newer therapies (oral and infusion disease-modifying drugs) and on those still currently under investigation. |
| first_indexed | 2024-12-16T23:03:51Z |
| format | Article |
| id | doaj.art-19c0850d39c64d26a2c3f21683d8c6f3 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-16T23:03:51Z |
| publishDate | 2021-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-19c0850d39c64d26a2c3f21683d8c6f32022-12-21T22:12:37ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-05-011210.3389/fneur.2021.676095676095Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and OpportunitiesMonica Margoni0Monica Margoni1Francesca Rinaldi2Paola Perini3Paolo Gallo4Paolo Gallo5Multiple Sclerosis Centre of the Veneto Region (CeSMuV), University Hospital of Padua, Padua, ItalyPadova Neuroscience Centre, University of Padua, Padua, ItalyMultiple Sclerosis Centre of the Veneto Region (CeSMuV), University Hospital of Padua, Padua, ItalyMultiple Sclerosis Centre of the Veneto Region (CeSMuV), University Hospital of Padua, Padua, ItalyMultiple Sclerosis Centre of the Veneto Region (CeSMuV), University Hospital of Padua, Padua, ItalyDepartment of Neurosciences, Medical School, University of Padua, Padua, ItalyTreatment of pediatric-onset multiple sclerosis (POMS) has been tailored after observational studies and data obtained from clinical trials in adult-onset multiple sclerosis (AOMS) patients. There are an increasing number of new therapeutic agents for AOMS, and many will be formally studied for use also in POMS. However, there are important efficacy and safety concerns regarding the use of these therapies in children and young adults. This review will discuss the current state of the art of POMS therapy and will focus on the newer therapies (oral and infusion disease-modifying drugs) and on those still currently under investigation.https://www.frontiersin.org/articles/10.3389/fneur.2021.676095/fullpediatric onset multiple sclerosisfirst-line therapiessecond-line therapiesefficacysafety |
| spellingShingle | Monica Margoni Monica Margoni Francesca Rinaldi Paola Perini Paolo Gallo Paolo Gallo Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities Frontiers in Neurology pediatric onset multiple sclerosis first-line therapies second-line therapies efficacy safety |
| title | Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities |
| title_full | Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities |
| title_fullStr | Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities |
| title_full_unstemmed | Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities |
| title_short | Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities |
| title_sort | therapy of pediatric onset multiple sclerosis state of the art challenges and opportunities |
| topic | pediatric onset multiple sclerosis first-line therapies second-line therapies efficacy safety |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2021.676095/full |
| work_keys_str_mv | AT monicamargoni therapyofpediatriconsetmultiplesclerosisstateoftheartchallengesandopportunities AT monicamargoni therapyofpediatriconsetmultiplesclerosisstateoftheartchallengesandopportunities AT francescarinaldi therapyofpediatriconsetmultiplesclerosisstateoftheartchallengesandopportunities AT paolaperini therapyofpediatriconsetmultiplesclerosisstateoftheartchallengesandopportunities AT paologallo therapyofpediatriconsetmultiplesclerosisstateoftheartchallengesandopportunities AT paologallo therapyofpediatriconsetmultiplesclerosisstateoftheartchallengesandopportunities |